Transplant Center

Research:

Integrated Therapeutics        Mukherjee (PI)        2006-Present
P04590
PROTECT- Pegylated Interferon Alfa-2B and Ribavirin after Orthotopic Liver Transplantation: Efficacy and Safety in Hepatitis C Recurrence Therapy
The major goal of this research study is to evaluate the effectiveness and safety of Pegylated interferon alfa-2b in combination with ribavirin in patients whose hepatitis c virus has recurred after liver transplantation.
Role: Co-Investigator

Novartis Pharmaceuticals Corp    Mukherjee (PI)        2006-Present
COLO400A2426
A Multicenter, Randomized, Open Label Study to Compare the Development of Liver Fibrosis at 12 Months After Transplantation for Hepatitis C Cirrhosis in Patients Receiving either Neoral or Tacrolimus
The major goal of this research study is to see if the time to recurrence of liver fibrosis is longer with Neoral than Tacrolimus.
Role: Co-Investigator

Genzyme Corporation            Grant (PI)            2005-Present
Investigator Initiated
A Randomized, Single-Center Trial Comparing Thymoglobulin Induction Therapy and Delayed Initiation of Tacrolimus to No Induction with Immediate Initiation of Tacrolimus in Liver Transplant Recipients to Assess the Impact on Renal Function
The major goal of this research study is explore Thymoglobulin induction and its impact on renal function in liver transplant patients.
Role:    Co- Investigator
NIH/NIDDK                Langnas (PI)            2005-Present
R01 HD045694
Functional Outcomes in Pediatric Liver Transplantation
The major goal of this project is to compare health-related quality of life of children who have had liver transplants to that of children in the general population.
Role:    Principal Investigator

NIH/NIDDK
5U01DK061693-02            Langnas (PI)            2004-Present   
SPLIT (Studies of Pediatric Liver Transplantation), A Multicenter, Prospective Study to Collect Scientific Data on Pediatric Liver Transplantation
The major goal of this research is designed to characterize and follow trends and indications for transplant, transplant techniques, and outcomes of pediatric isolated liver transplant recipients into one registry.
Role:    Principal Investigator

Novartis Pharmaceuticals        Langnas (PI)            2004-Present
RAD001A 2401
A Facilitated Access Program to Provide Everolimus (RAD) for Maintenance Patients Completing Therapy in RAD Trials in Solid Organ Transplantation
The major goal of this research is to continue to monitor long-term safety and efficacy of Everolimus in recipients of solid organ transplants.
Role:    Principal Investigator

Wyeth Research             Grant (PI)            2002-Present
0468H1-313       
A Randomized, Open-Label, Comparative Evaluation of Conversion from Calcineurin Inhibitor (CI) Treatment to Sirolimus Treatment versus Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipients Undergoing Maintenance Therapy
The major goal of this research is to determine whether kidney function can be protected through the use of Sirolimus maintenance therapy alone without increasing the risk of rejection.
Role: Co-Investigator
www.ncbi.nlm.nih.gov/pubmed/16948952